Marksans Pharma Limited (BOM:524404)

Marksans Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	31,717	29,509	26,228	21,774	18,521	14,908
Revenue Growth	19.59%	12.51%	20.46%	17.56%	24.23%	8.33%
Gross Profit Gross Profit Growth	17,522	16,131	14,247	11,034	9,120	7,613
Operating Income Operating Income Growth	6,137	5,026	4,493	3,843	2,877	2,141
Net Income Net Income Growth	5,168	4,179	3,806	3,137	2,663	1,868
Earnings Per Share EPS Growth	11.40	9.22	8.40	6.92	6.41	4.56
EPS Growth	47.24%	9.79%	21.36%	7.96%	40.44%	-21.68%

Revenue by Geography

Chart

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
United States and North America United States and North America Growth	15,335	12,366	9,181	7,746	6,351
Europe and The United Kingdom Europe and The United Kingdom Growth	10,150	10,298	9,430	7,676	6,091
Australia and New Zealand Australia and New Zealand Growth	3,031	2,528	2,188	2,095	1,798
Rest of World Rest of World Growth	994.34	1,037	974.49	1,004	554.8
Total Total Growth	29,509	26,228	21,774	18,521	14,908

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	9,909	9,909	7,060	7,013	7,158	3,467
Total Debt Total Debt Growth	3,434	3,434	3,219	2,441	1,229	1,108
Net Cash (Debt) Net Cash Growth	6,475	6,475	3,841	4,572	5,929	2,359
Net Cash Growth	68.59%	68.59%	-16.00%	-22.88%	151.30%	36.10%
Net Cash Per Share Net Cash Per Share Growth	14.28	14.29	8.48	10.09	14.27	5.76

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	4,581	2,067	2,304	2,374	992.57
Capital Expenditures CapEx Growth	-	-1,305	-1,729	-2,088	-536.31	-463.3
Free Cash Flow Free Cash Flow Growth	-	3,276	337.45	215.69	1,838	529.27
Free Cash Flow Growth	-	870.81%	56.45%	-88.26%	247.24%	-59.95%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	55.24%	54.66%	54.32%	50.67%	49.24%	51.07%
Operating Margin	19.35%	17.03%	17.13%	17.65%	15.53%	14.36%
Pretax Margin	21.77%	19.00%	19.21%	19.45%	18.23%	16.60%
Profit Margin	16.29%	14.16%	14.51%	14.41%	14.38%	12.53%
FCF Margin	-	11.10%	1.29%	0.99%	9.92%	3.55%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	0.900	0.900	0.800	0.600	0.500	0.250
Dividend Per Share Growth	12.50%	12.50%	33.33%	20.00%	100.00%	0%
Dividend Yield	0.27%	0.57%	0.36%	0.40%	0.72%	0.56%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	28.18	17.01	26.49	21.94	11.98	9.97
P/FCF Ratio	44.45	21.70	298.76	319.14	17.36	35.20
PS Ratio	4.59	2.41	3.84	3.16	1.72	1.25

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 18, 2026

Data Sources Report a data error